TCRT

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

Alaunos Reports Positive ALN1003 Preclinical Readout in Diet-Induced Obese Mice

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Alaunos Therapeutics announced integrated preclinical results for ALN1003 in diet-induced obese (DIO) mice, showing improvements across weight, body composition, insulin-resistance biomarkers, adipose signaling, and hepatic health in two non-GLP studies. An accompanying investor presentation is available; however, all findings remain non-human and require cautious interpretation and follow-up studies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>ALN1003 shows multi-axis improvements in two non-GLP DIO mouse studies. Supports continued preclinical development.</li><li>Key readouts: body weight/fat mass, insulin-resistance biology, adipose signaling, and hepatic markers improve.</li><li>Integrated data presented in a non-confidential investor deck.</li><li>Company cash runway extends into Q2 2026; financing needed to continue operations.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Alaunos Therapeutics, Inc. (TCRT)</strong>: Integrated preclinical ALN1003 readout; data and investor deck published May 2026.</li><li><strong>Globe Newswire (N/A)</strong>: Disseminated the press release; not a market participant.</li></ul>
  </section>

  <section data-block="category">
    <h3>Research Analysis</h3>
    <p>Category Type: Research Analysis. The piece centers on preclinical data and the development roadmap for ALN1003, signaling a potential future catalyst but lacking clinical data or near-term revenue impact.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ALN1003 preclinical readout released; could spark near-term investor interest.</li><li>Company cash runway into Q2 2026; need for additional financing creates financial risk.</li><li>Non-GLP data; no human results yet, limiting immediate valuation impact.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Two non-GLP DIO mouse studies underpin the readout.</li><li>DIO Study 1: 48 days; Day 33 -12.9% BW; Day 48 -10.3% BW.</li><li>DIO Study 2: 18 days; high-dose -30.5% BW; fat loss -21.9%.</li><li>Liver weight reductions: 43% (DIO1); up to 55% (DIO2 high-dose).</li><li>ALT/AST/ALP reductions; bilirubin trend toward lower levels.</li><li>Cash: $0.354 million as of 3/31/2026; runway to Q2 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral stance; upside if follow-on data and financing enable next steps within 6–12 months.</p>
  </section>
</section>


<article>
  <p><strong>Alaunos Therapeutics, Inc. (NASDAQ:</strong> TCRT<strong>)</strong> today reported an integrated preclinical readout for ALN1003, the company’s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-GLP diet-induced obesity (DIO) mouse studies previously reported on March 2, 2026 and May 18, 2026, together with newly assembled cross-study analyses presented in an accompanying non-confidential slide deck published today. This strengthens the case for continued preclinical development of ALN1003 and informs future controlled follow-up studies.</p>

  <section>
    <h2>Overview of ALN1003 Preclinical Readout</h2>
    <ul>
      <li><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li>
      <li><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li>
    </ul>
    <p>Viewed together, the data show treatment-associated <em>improvements across key biological drivers of metabolic disease</em> including body weight, body composition, insulin-resistance biology, adipose endocrine signaling, and hepatic biology. The company notes that metabolic syndrome involves interconnected dysfunction across multiple organ systems, and that a multi-axis profile may be important for future therapeutic approaches. <strong>TCRT</strong> emphasizes that these are early, non-GLP findings in a mouse model and must be interpreted with appropriate caution.</p>
    <p>“What we believe makes the ALN1003 preclinical profile distinctive is consistency of treatment-associated changes across several metabolic readouts,” said Holger Weis, CEO of Alaunos. “ALN1003-treated animals showed improvement in body weight, body composition, insulin-resistance biomarkers, adipose endocrine markers, and selected liver pathology. These are early, non-GLP findings in a mouse model and must be interpreted with appropriate caution — but they support continued preclinical development of ALN1003 and further evaluation in controlled follow-up studies.”</p>
  </section>

  <section>
    <h2>Two Complementary DIO Studies Form the Readout</h2>
    <p>The two DIO mouse studies underpinning this readout were designed to address different questions and, taken together, describe a single multi-axis preclinical profile. The longer-duration study (DIO Study 1) spanned 48 days and evaluated ALN1003 administered orally, twice daily, at a single dose level. The study captured the fullest expression of the multi-axis profile, including body weight, insulin-resistance biology, adipose endocrine signaling, and hepatic biology. The shorter study (DIO Study 2) spanned 18 days and used dose-ranging administration in drinking water at low, medium, and high dose levels, revealing dose-related changes in body weight, body composition, liver weight, glucose, and total cholesterol.</p>
    <p>Interpretation of DIO Study 2 should consider dose-related reductions in water consumption and apparent dose aversion, which may confound attribution of effects solely to drug exposure in this administration paradigm; the Company is pursuing formulation optimization and dedicated PK/tolerability work.</p>
  </section>

  <section>
    <h2>Multi-Axis Findings Across Both DIO Studies</h2>

    <h3>Body Weight and Food Intake</h3>
    <p>In DIO Study 1 (48 days, oral BID), mean percent change in body weight for ALN1003-treated mice peaked at <strong>-12.9%</strong> (p&lt;0.0001) on Day 33 and was <strong>-10.3%</strong> (p&lt;0.0001) at Day 48 relative to DIO controls. In DIO Study 2 (18 days, drinking water), mean percent change in body weight for ALN treated mice relative to DIO controls for the treatment period on Day 14 was <strong>-2.1%</strong>, <strong>-10.4%</strong> (p&lt;0.0001) and <strong>-30.5%</strong> (p&lt;0.0001) in the low, mid and high dose, respectively. In DIO Study 1, ALN1003 reduced cumulative food consumption versus DIO control (<strong>347.5 g/cage</strong> vs <strong>425.0 g/cage</strong>; nominal p&lt;0.05). In DIO Study 2 (18 days, drinking water), weight loss was dose-dependent across the three dose levels, with the caveats noted above regarding water intake.</p>

    <h3>Body Composition</h3>
    <p>In DIO Study 2, body composition assessed by Bruker Minispec<sup>™</sup> LF90II showed dose-related shifts consistent with a metabolically favorable profile. At Day 17 in the high-dose group, fat as a percentage of body weight changed by <strong>-21.9%</strong> (nominal p&lt;0.0001), lean as a percentage of body weight changed by <strong>+17.2%</strong> (nominal p&lt;0.0001), and fat in grams declined by <strong>44.6%</strong> (<strong>-8.9 g</strong>; nominal p&lt;0.0001). Absolute lean and fluid decreases should be interpreted in the context of overall weight loss and reduced water intake.</p>

    <h3>Insulin-Resistance Biology</h3>
    <p>In DIO Study 1, ALN1003 was associated with lower fasting insulin and lower HOMA-IR (a fasting glucose/insulin index of insulin-resistance), including after adjustment for body fat (ANCOVA p=0.0006).</p>

    <h3>Adipose Endocrine Signaling</h3>
    <p>In DIO Study 1, ALN1003 was associated with numerically lower leptin, significantly higher adiponectin, and a significantly higher adiponectin-to-leptin ratio. These findings are consistent with favorable adipose endocrine biomarker changes in this preclinical model.</p>

    <h3>Hepatic Biology — Liver Weight, Enzymes, and Histology</h3>
    <p>In DIO Study 1, ALN1003 reduced liver weight by <strong>43%</strong> (<strong>p&lt;0.0001</strong>) relative to untreated controls. Long-term administration was associated with significantly lower ALT (<strong>p&lt;0.0001</strong>), AST (<strong>p&lt;0.0001</strong>), and ALP (<strong>p&lt;0.0001</strong>), with a trend toward lower total bilirubin (nominal p=0.058). In DIO Study 2, end-of-study (Day 18) liver weight reductions versus DIO control were <strong>-6.8%</strong>, <strong>-20.5%</strong>, and <strong>-55.0%</strong> (<strong>nominal p&lt;0.01</strong>) in the low, medium, and high dose groups, respectively.</p>
  </section>

  <section>
    <h2>Context and Next Steps</h2>
    <p>Metabolic syndrome involves dysfunction across insulin resistance, adipose tissue function, and hepatic lipid accumulation. Alaunos believes a multi-system therapeutic profile may be advantageous for addressing obesity and related metabolic disorders. These preclinical findings support ongoing development of ALN1003 and inform the design of future studies to confirm translational relevance in controlled settings.</p>
  </section>
</article>

Alaunos Therapeutics announced integrated preclinical results for ALN1003 in diet-induced obese (DIO) mice, showing improvements across weight, body composition, insulin-resistance biomarkers, adipose signaling, and hepatic health in two non-GLP studies. An accompanying investor presentation is available; however, all findings remain non-human and require cautious interpretation and follow-up studies.

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Research Analysis

Related News